Aerie Pharmaceuticals Announces Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- Six Flags to move headquarters from Charlotte to Arlington, Texas
Aerie Pharma (AERI) Prices $75M Common Stock Offering at $53.75/Share; $50M in Common Stock Sold Through ATM Program
May 26, 2017 6:31 AM EDTAerie Pharmaceuticals, Inc. (NASDAQ: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that it has priced its registered underwritten public offering (the Underwritten Offering) of $75 million of shares of its common stock at a price to the public of $53.75 per share. The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced.... More
